Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Background: Mavacamten, a first-in-class cardiac myosin inhibitor and the only approved cardiac myosin inhibitor worldwide, improved clinical symptoms and health status in patients with symptomatic obstructive hypertrophic cardiomyopathy (HCM) in phase 3 EXPLORER-HCM (Clinical Study to Evaluate Mavacamten [MYK-461] in Adults With Symptomatic Obstructive Hypertrophic Cardiomyopathy; NCT03470545) and EXPLORER-CN (A Study to Evaluate the Efficacy and Safety of Mavacamten in Chinese Adults With Symptomatic Obstructive HCM; NCT05174416).

Objectives: The purpose of this work was to study the effect of mavacamten on cardiac structure and function by cardiac magnetic resonance (CMR) imaging in Chinese participants in EXPLORER-CN.

Methods: Eligible patients with obstructive HCM underwent CMR imaging at screening and week 30. Change from baseline to week 30 in left ventricular (LV) mass index was analyzed as a prespecified secondary outcome. Prespecified exploratory outcomes included changes in cellular hypertrophy, cardiac structure and function, and myocardial fibrosis by CMR.

Results: Among 81 patients randomized, 58 patients (mean age 51.2 years, 74.1% men) with CMR data available were analyzed (mavacamten, n = 39; placebo, n = 19). After 30 weeks, greater reductions from baseline were observed (mean between-group difference) with mavacamten vs placebo in LV mass index (-30.8 g/m [95% CI: -41.5 to -20.1 g/m]), maximal LV wall thickness (-3.5 mm [95% CI: -4.7 to -2.4 mm]), and maximal left atrial volume index (-18.3 mL/m [95% CI: -26.7 to -9.8 mL/m]); all nominal P < 0.001. Reduction from baseline to week 30 in global mass of late gadolinium enhancement by 6 SDs was also observed with mavacamten vs placebo (mean between-group difference, -2.0 g [95% CI: -11.9 to 8.0 g]; nominal P = 0.007).

Conclusions: At 30 weeks, improvements were observed in measures of cardiac structure and function, with reductions in indicators of myocardial fibrosis, in the mavacamten vs the placebo group. (A Study to Evaluate the Efficacy and Safety of Mavacamten in Chinese Adults With Symptomatic Obstructive HCM; NCT05174416).

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jacasi.2025.05.015DOI Listing

Publication Analysis

Top Keywords

symptomatic obstructive
16
mavacamten placebo
16
obstructive hypertrophic
12
hypertrophic cardiomyopathy
12
study evaluate
12
adults symptomatic
12
obstructive hcm
12
cardiac structure
12
structure function
12
mavacamten
9

Similar Publications

Subaortic membrane (SAM) is a subtype of left ventricular outflow obstruction, rarely seen in adults. In some cases, SAM may be associated with other congenital defects. The association of patent ductus arteriosus (PDA) and SAM is the rarest, especially in adult patients.

View Article and Find Full Text PDF

Background: Alcohol septal ablation (ASA) is an established therapy for symptomatic hypertrophic obstructive cardiomyopathy (HOCM) in patients unresponsive to medical treatment. However, comprehensive assessment of ASA outcomes remains challenging. This study aimed to evaluate the impact of institutional experience and patient characteristics on achieving complete clinical and haemodynamic response (CCHR), a novel composite outcome integrating long-term symptomatic, haemodynamic, safety, and major clinical endpoints, including survival and resuscitation.

View Article and Find Full Text PDF

Rationale: AIRFLOW-3 was a 1:1 randomized, double blind, sham controlled trial of the d'Nerva Targeted Lung Denervation (TLD) System in patients with COPD.

Objective: Evaluate the impact of TLD on COPD exacerbations compared to optimal medical treatment.

Methods: AIRFLOW-3 patients were symptomatic (CAT ≥10) with moderate to very severe airflow obstruction (25% ≤ FEV ≤ 80% predicted) and GOLD E status (≥2 moderate or ≥1 severe exacerbation over prior 12 months).

View Article and Find Full Text PDF

Prospective Evaluation of Thrombotic Complications After Internal Jugular Vein Cannulation for External Bypass.

J Cardiothorac Vasc Anesth

August 2025

Goethe-University Frankfurt, University Hospital Frankfurt, Department of Anaesthesiology, Intensive Care Medicine and Pain Therapy, Frankfurt, Germany; Department of Anesthesiology and Intensive Care Medicine, Rheinische Friedrich-Wilhelms-University, University Hospital Bonn, Bonn, Germany.

Objectives: To determine the incidence and subsequent complications of internal jugular vein (IJV) thrombosis after cannulation performed during cardiopulmonary bypass (CPB) to ensure adequate venous drainage during minimally invasive cardiac surgery.

Design: Single-center observational trial SETTINGS: Intensive care postoperative monitoring of cardiac surgery patients and diagnosis of IJV thrombi at a university tertiary hospital during the 13-month study period from December 1, 2022, to January 11, 2024.

Participants: 44 patients undergoing catheterization of the IJV for total CPB.

View Article and Find Full Text PDF

The surgical approach of ureteral stricture has changed dramatically over the past 15 years with the rise of robotic upper urinary tract reconstruction. This study aimed to evaluate the outcomes of all robotic ureteral reconstructions performed at a single academic center for ureteral stricture and to assess the predictive factors of stricture recurrence. The charts of all patients who underwent robot-assisted ureteral reconstruction between 2013 and 2024 at a single academic center were retrospectively reviewed.

View Article and Find Full Text PDF